Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Cuts Holdings in Axsome Therapeutics, Inc. $AXSM

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lowered its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 14.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 278,835 shares of the company’s stock after selling 47,483 shares during the quarter. Axsome Therapeutics accounts for about 4.5% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings, making the stock its 6th biggest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings in Axsome Therapeutics were worth $50,926,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Axsome Therapeutics by 6.0% during the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after acquiring an additional 235,626 shares during the last quarter. Wellington Management Group LLP boosted its position in Axsome Therapeutics by 84.1% during the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after acquiring an additional 609,516 shares during the last quarter. Geode Capital Management LLC boosted its position in Axsome Therapeutics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock valued at $184,544,000 after acquiring an additional 12,549 shares during the last quarter. Invesco Ltd. boosted its position in Axsome Therapeutics by 73.3% during the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock valued at $120,303,000 after acquiring an additional 419,008 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Axsome Therapeutics by 5.8% during the 2nd quarter. State Street Corp now owns 958,503 shares of the company’s stock worth $100,058,000 after purchasing an additional 52,483 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Trading Up 0.3%

AXSM opened at $246.34 on Thursday. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32. Axsome Therapeutics, Inc. has a fifty-two week low of $96.09 and a fifty-two week high of $256.00. The firm has a market capitalization of $12.68 billion, a PE ratio of -66.04 and a beta of 0.61. The company’s 50-day moving average is $207.58 and its 200 day moving average is $180.70.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. The business’s revenue was up 57.4% on a year-over-year basis. As a group, research analysts predict that Axsome Therapeutics, Inc. will post -2.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Truist Financial raised shares of Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Wells Fargo & Company increased their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Mizuho increased their price objective on shares of Axsome Therapeutics from $228.00 to $310.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Guggenheim increased their price objective on shares of Axsome Therapeutics from $245.00 to $260.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Finally, Royal Bank Of Canada increased their price objective on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $251.26.

Insider Buying and Selling

In related news, Director Susan Mahony sold 300 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $237.21, for a total value of $71,163.00. Following the sale, the director owned 1,129 shares in the company, valued at $267,810.09. This represents a 20.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mark Coleman sold 643 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $249.00, for a total transaction of $160,107.00. Following the completion of the sale, the director owned 30,389 shares in the company, valued at $7,566,861. This represents a 2.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 113,400 shares of company stock worth $26,595,598 over the last ninety days. Insiders own 20.60% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.